as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹581.85
Change
-9.15 (-1.55%)
Open
₹591.1
Prev. Close
₹591.0
Day High
₹591.1
Day Low
₹581.4
Volume Analysis
Traded
20,643
Delivered
14,894
Delivery %
72.15%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹597.86 | ₹594.48 | ₹588.16 | ₹584.78 | ₹578.46 | ₹575.08 | ₹568.76 |
| Fibonacci | ₹594.48 | ₹590.77 | ₹588.49 | ₹584.78 | ₹581.07 | ₹578.79 | ₹575.08 |
| Camarilla | ₹584.52 | ₹583.63 | ₹582.74 | ₹584.78 | ₹580.96 | ₹580.07 | ₹579.18 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+21.27%
1 Week
-2.1%
1 Month
-5.38%
3 Months
-6.47%
6 Months
-3.81%
1 Year
+9.42%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹610.9
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.14%
Net margin 13.83% × asset turnover 0.75x × equity multiplier 1.17x
Company Overview
Sector
Healthcare
Market Cap
₹1,182 Cr
P/E (TTM)
12.2
ROE
12.3%
Book Value
₹378.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Lincoln Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 62/100. The strongest factor is Financial Strength (100/100), while Growth (41/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
62/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −The company has delivered a poor sales growth of 9.61% over past five years.
- −Company has a low return on equity of 13.8% over last 3 years.
- −Earnings include an other income of Rs.42.4 Cr.
- −Dividend payout has been low at 4.11% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Mr. Manoj Rai, Sr. General Manager-QA, resigned effective 24 September 2026.
Pradeep Kumar Yadav appointed Senior General Manager-Quality Assurance effective 24 September 2026.
Newspaper Publication for Notice of 32nd Annual General Meeting.
32nd AGM on 30 Sep 2026 at 11:00 AM; annual report 2025-26 shared with shareholders.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses + | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating Profit | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 15.0% | 20.0% | 20.0% | 13.0% | 15.0% | 18.0% | 16.0% | 16.0% | 15.0% | 16.0% | 14.0% | 13.0% | 15.0% |
| Other Income + | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 25.0% | 25.0% | 26.0% | 16.0% | 20.0% | 24.0% | 28.0% | 29.0% | 22.0% | 31.0% | 18.0% | 30.0% | 24.0% |
| Net Profit + | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS in Rs | 9 | 14 | 14 | 9 | 12 | 13 | 10 | 6 | 14 | 10 | 14 | 6 | 18 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 671 | 694 |
| Expenses + | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | 573 | 593 |
| Operating Profit | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 98 | 101 |
| OPM % | 10.0% | 10.0% | 13.0% | 15.0% | 18.0% | 17.0% | 21.0% | 20.0% | 18.0% | 17.0% | 16.0% | 15.0% | 15.0% |
| Other Income + | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | 33 | 42 |
| Interest | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 14 | 15 |
| Profit before tax | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 116 | 128 |
| Tax % | 24.0% | 28.0% | 25.0% | 25.0% | 22.0% | 23.0% | 26.0% | 28.0% | 27.0% | 24.0% | 25.0% | 24.0% | — |
| Net Profit + | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS in Rs | 9 | 15 | 14 | 17 | 24 | 26 | 31 | 35 | 36 | 47 | 41 | 44 | 48 |
| Dividend Payout % | 11.0% | 7.0% | 9.0% | 9.0% | 6.0% | 6.0% | 5.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 95 | 124 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | 738 |
| Borrowings + | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | 4 |
| Other Liabilities + | 70 | 56 | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | 128 |
| Total Liabilities | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |
| Fixed Assets + | 66 | 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | 191 |
| CWIP | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 | 5 |
| Investments | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | 209 |
| Other Assets + | 190 | 174 | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | 486 |
| Total Assets | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 | 890 |
| Equity Capital | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 25 | 45 | 25 | 27 | 53 | 75 | 69 | 76 | 39 | 63 | 93 | 106 |
| Cash from Investing Activity + | 7 | -42 | -25 | -12 | -18 | -31 | -64 | -78 | -37 | -57 | -79 | -98 |
| Cash from Financing Activity + | -32 | -3 | 0 | -11 | -36 | -38 | -6 | -3 | -4 | -5 | -6 | 0 |
| Net Cash Flow | -1 | 0 | 0 | 3 | -1 | 7 | -1 | -4 | -2 | 1 | 8 | 8 |
| CFO/OP | 109 | 126 | 74 | 68 | 104 | 137 | 102 | 104 | 77 | 89 | 117 | 135 |
| Free Cash Flow | 21 | 11 | 7 | 17 | 38 | 68 | 61 | 31 | 26 | 24 | 74 | 82 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 46.87% | 46.92% | 46.49% | 46.24% | 45.04% | 45.07% | 45.23% | 45.08% | 45.49% | 45.51% | 43.94% | 45.36% |
| Promoters | 50.53% | 49.81% | 49.54% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| FII | 2.59% | 3.22% | 3.93% | 3.95% | 5.19% | 5.16% | 5.0% | 5.13% | 4.73% | 4.7% | 5.2% | 4.6% |
| DII | 0.0% | 0.06% | 0.05% | 0.04% | 0.0% | 0.0% | 0.0% | 0.01% | 0.01% | 0.01% | 1.08% | 0.27% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Lincoln Pharma Ltd (this stock) | 1,182 | 12.2 | 1.56 | 12.3% |
| 3b Blackbio Dx Ltd. | 1,207 | 21.7 | 3.72 | 19.8% |
| Sigachi Industries Ltd | 1,125 | 50.0 | 2.16 | 5.78% |
| Laxmi Dental Limited | 1,097 | 31.6 | 4.49 | 14.8% |
| Bharat Parenterals Ltd. | 1,077 | — | 3.3 | -2.54% |
| Themis Medicare Ltd. | 1,077 | 624.0 | 2.7 | 0.41% |
| Gpt Healthcare Limited | 1,331 | 32.0 | — | 28.5% |
Which Mutual Funds Hold Lincoln Pharma Ltd?
Frequently Asked Questions about Lincoln Pharma Ltd
Lincoln Pharma Ltd (LINCOLN) closed at ₹581.85 on NSE on 28 September 2026, down 9.15 (1.55%) from the previous close.
Lincoln Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol LINCOLN.
Lincoln Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 12.2.
Lincoln Pharma Ltd has a dividend yield of 0.3%.
Lincoln Pharma Ltd's 52-week high is ₹770.0 and its 52-week low is ₹440.0.
Lincoln Pharma Ltd has a market capitalisation of ₹1,182 crore.
Lincoln Pharma Ltd has a TopFund Quality Score of 62/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Lincoln Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.